A Multicenter, Open-label, Randomized, Controlled, Phase 2 Trial Evaluating Whether Low Molecular Heparin Could Improve Pregnancy Outcomes With Protein S Deficiency
Latest Information Update: 30 Jan 2025
Price :
$35 *
At a glance
- Drugs Aspirin (Primary) ; Enoxaparin sodium (Primary)
- Indications Protein S deficiency
- Focus Therapeutic Use
- 30 Jan 2025 New trial record
- 10 Dec 2024 Primary endpoint (Rate of livebirth Incidents of livebirth From date of randomization until delivery, assessed up to 42 months) has not been met, according to the results presented at the 66th American Society of Hematology Annual Meeting and Exposition.
- 10 Dec 2024 Results presented at the 66th American Society of Hematology Annual Meeting and Exposition